SG11202105413QA - Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease - Google Patents
Methods for diagnosing and/or treating acute or chronic liver, kidney or lung diseaseInfo
- Publication number
- SG11202105413QA SG11202105413QA SG11202105413QA SG11202105413QA SG11202105413QA SG 11202105413Q A SG11202105413Q A SG 11202105413QA SG 11202105413Q A SG11202105413Q A SG 11202105413QA SG 11202105413Q A SG11202105413Q A SG 11202105413QA SG 11202105413Q A SG11202105413Q A SG 11202105413QA
- Authority
- SG
- Singapore
- Prior art keywords
- diagnosing
- kidney
- methods
- lung disease
- chronic liver
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18382853 | 2018-11-26 | ||
PCT/EP2019/082606 WO2020109316A1 (fr) | 2018-11-26 | 2019-11-26 | Procédés de diagnostic et/ou de traitement d'une maladie hépatique, rénale ou pulmonaire aiguë ou chronique |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202105413QA true SG11202105413QA (en) | 2021-06-29 |
Family
ID=64665077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202105413QA SG11202105413QA (en) | 2018-11-26 | 2019-11-26 | Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220026444A1 (fr) |
EP (1) | EP3886851A1 (fr) |
JP (1) | JP2022515976A (fr) |
KR (1) | KR20210096143A (fr) |
CN (1) | CN113271943A (fr) |
AU (1) | AU2019390667A1 (fr) |
BR (1) | BR112021010174A2 (fr) |
CA (1) | CA3120842A1 (fr) |
IL (1) | IL283472A (fr) |
MX (1) | MX2021006210A (fr) |
SG (1) | SG11202105413QA (fr) |
WO (1) | WO2020109316A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230018429A (ko) * | 2020-05-27 | 2023-02-07 | 아소시아시온 센트로 데 인베스티가시온 코오페라티바 엔 비오시엔시아스-시스 비오구네 | 세포에서 cnnm4의 발현을 억제하기 위한 핵산 |
KR102629955B1 (ko) * | 2021-02-19 | 2024-01-25 | 가톨릭대학교 산학협력단 | Ewsr1의 발현 또는 활성 촉진제를 포함하는 비알콜성 지방간염 예방 또는 치료용 약학적 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2323638A1 (fr) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Systemes de proteines adressables |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
WO2016205534A1 (fr) * | 2015-06-16 | 2016-12-22 | Lazo John S | Inhibiteurs de ptp4a3 pour le traitement du cancer |
US10655126B2 (en) * | 2015-07-10 | 2020-05-19 | University Of Vermont And State Agricultural College | Methods and compositions to treat drug-induced diseases and conditions |
-
2019
- 2019-11-26 JP JP2021529704A patent/JP2022515976A/ja active Pending
- 2019-11-26 MX MX2021006210A patent/MX2021006210A/es unknown
- 2019-11-26 CN CN201980088780.0A patent/CN113271943A/zh active Pending
- 2019-11-26 BR BR112021010174A patent/BR112021010174A2/pt not_active Application Discontinuation
- 2019-11-26 CA CA3120842A patent/CA3120842A1/fr active Pending
- 2019-11-26 US US17/297,045 patent/US20220026444A1/en active Pending
- 2019-11-26 AU AU2019390667A patent/AU2019390667A1/en active Pending
- 2019-11-26 EP EP19813264.9A patent/EP3886851A1/fr active Pending
- 2019-11-26 WO PCT/EP2019/082606 patent/WO2020109316A1/fr unknown
- 2019-11-26 SG SG11202105413QA patent/SG11202105413QA/en unknown
- 2019-11-26 KR KR1020217018933A patent/KR20210096143A/ko active Search and Examination
-
2021
- 2021-05-26 IL IL283472A patent/IL283472A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019390667A1 (en) | 2021-07-22 |
EP3886851A1 (fr) | 2021-10-06 |
MX2021006210A (es) | 2021-08-19 |
JP2022515976A (ja) | 2022-02-24 |
KR20210096143A (ko) | 2021-08-04 |
WO2020109316A1 (fr) | 2020-06-04 |
IL283472A (en) | 2021-07-29 |
CN113271943A (zh) | 2021-08-17 |
BR112021010174A2 (pt) | 2021-11-03 |
CA3120842A1 (fr) | 2020-06-04 |
US20220026444A1 (en) | 2022-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202103877SA (en) | Privacy preserving validation and commit architecture | |
EP3438282A4 (fr) | Procédé de criblage de substances candidates pour un composant actif pour prévenir ou traiter au moins une maladie choisie dans le groupe constitué d'une hypofonction rénale, une maladie rénale chronique et une insuffisance rénale | |
IL279432A (en) | Systems and methods for determining cardiac performance | |
EP3647422A4 (fr) | Kit, dispositif et procédé de détection d'un cancer du poumon | |
EP3792363C0 (fr) | Méthode et kit pour identifier l'état d'un cancer du poumon | |
IL263025A (en) | A method and system for predicting the prognosis for kidney disease | |
IL286603A (en) | Treatment employing anti-il-13r antibody or binding fragment thereof | |
IL283472A (en) | Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease | |
EP3801069A4 (fr) | Polythérapie pour maladie ou trouble associé à pi3k | |
SG10201913400QA (en) | Methods for treating lung disorders | |
IL276009A (en) | Kits and methods for diagnosing lung cancer | |
EP3674710C0 (fr) | Méthode de prédiction ou de diagnostic d'hépatopathie pour les patients avec nafld | |
GB2581922B (en) | Preventing long running transactions from holding record locks | |
LT3630164T (lt) | Dulagliutidas, skirtas lėtinės inkstų ligos gydymui | |
EP3342864A4 (fr) | Procédé de diagnostic d'une maladie auto-immune, biomarqueur de diagnostic d'une maladie auto-immune, et agent de prévention ou de traitement d'une maladie auto-immune | |
DK3269735T3 (da) | Antistof mod sclerostin, antigenbindende fragment og medicinsk anvendelse deraf | |
SG11202002088TA (en) | Methods and compositions for treating chronic lung diseases | |
EP3217987A4 (fr) | Inhibiteurs de sglt-2 pour le traitement de troubles métaboliques chez des patients présentant une insuffisance rénale ou une maladie rénale chronique | |
ZA201906997B (en) | Methods of diagnosing and treating chronic kidney disease | |
EP3307781B8 (fr) | Anticorps, composés et écrans permettant l'identification et le traitement la cachexie ou pré-cachexie | |
EP3695224A4 (fr) | Biomarqueurs de pronostic et de progression d'une néphropathie chronique | |
EP4164624A4 (fr) | Méhodes de traitement ou de prévention de maladie rénale chronique | |
PL3543702T3 (pl) | Sposoby badania przesiewowego osobnika pod kątem ryzyka przewlekłej choroby nerek i sposób realizowany komputerowo | |
EP3273965A4 (fr) | Composition et procédés de traitement de maladie rénale chronique | |
EP3795983A4 (fr) | Procédé et système de diagnostic du cancer du poumon fondé sur l'air expiré |